NeuroBo Pharma enters term sheet with MThera Pharma to out-license NB-01

NeuroBo Pharmaceuticals announced that it has entered into a term sheet with MThera Pharma Co., Ltd. ) which provides for the terms under which NeuroBo will out-license the worldwide rights, outside of Korea, for NB-01 for the treatment of painful diabetic neuropathy to MTHERA. The term sheet allows MTHERA to conduct research in order to seek new patents for NB-01 and conduct clinical trials, including, but not limited to, a potential Phase 3 clinical trial in the United States for the future commercialization of NB-01. The financial terms of the term sheet, which are binding, were not disclosed.